Surgical Site Infections (SSIs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
- Published Date : September 4, 2025
- Updated On : January 29, 2026
- Pages : 153
Surgical Site Infections (SSIs) Market Outlook
Thelansis’s “Surgical Site Infections (SSIs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Surgical Site Infections treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Surgical Site Infections (SSIs) Overview
Surgical Site Infections (SSIs) are infections occurring at or near a surgical incision within 30 days of a procedure, or within 90 days if an implant is placed, and represent one of the most common healthcare-associated infections in clinical practice. SSIs are classified into superficial incisional, deep incisional, and organ/space infections based on the depth of involvement, with the latter carrying the greatest clinical severity. The most frequently implicated pathogens include Staphylococcus aureus, MRSA, coagulase-negative staphylococci, Escherichia coli, and Pseudomonas aeruginosa, with polymicrobial infections particularly common in abdominal and colorectal procedures. Key risk factors encompass diabetes, obesity, immunosuppression, prolonged surgical duration, and degree of wound contamination. Patients typically present with localized erythema, swelling, purulent discharge, wound dehiscence, and systemic signs of infection. Prevention remains central to SSI management through preoperative antisepsis, appropriate antibiotic prophylaxis, and perioperative glycemic and temperature control, while treatment relies on wound debridement and culture-directed antibiotic therapy, with rising antimicrobial resistance posing an increasing challenge to effective management.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Surgical Site Infections (SSIs) Market Outlook
Thelansis’s “Surgical Site Infections (SSIs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Surgical Site Infections treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Surgical Site Infections (SSIs) Overview
Surgical Site Infections (SSIs) are infections occurring at or near a surgical incision within 30 days of a procedure, or within 90 days if an implant is placed, and represent one of the most common healthcare-associated infections in clinical practice. SSIs are classified into superficial incisional, deep incisional, and organ/space infections based on the depth of involvement, with the latter carrying the greatest clinical severity. The most frequently implicated pathogens include Staphylococcus aureus, MRSA, coagulase-negative staphylococci, Escherichia coli, and Pseudomonas aeruginosa, with polymicrobial infections particularly common in abdominal and colorectal procedures. Key risk factors encompass diabetes, obesity, immunosuppression, prolonged surgical duration, and degree of wound contamination. Patients typically present with localized erythema, swelling, purulent discharge, wound dehiscence, and systemic signs of infection. Prevention remains central to SSI management through preoperative antisepsis, appropriate antibiotic prophylaxis, and perioperative glycemic and temperature control, while treatment relies on wound debridement and culture-directed antibiotic therapy, with rising antimicrobial resistance posing an increasing challenge to effective management.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)